If You're a Hims Customer, Here's the Plain-English Version
Big platform changes can be confusing, especially when they affect a medication you depend on. So let's keep this simple. Hims partnered with Novo Nordisk, stopped promoting compounded GLP-1s, and is steering customers toward FDA-approved Wegovy. If that affects you, the main thing is to understand what's changing and plan ahead — no panic required.
We'll break down what the deal is, why it's happening, and exactly what you should do if you've been getting compounded semaglutide through the platform. A little proactive planning here means you won't get caught with a gap in your medication.
What the Deal Is
Hims partnered with Novo Nordisk — the maker of Wegovy — and moved away from promoting compounded semaglutide. Instead, the platform now offers FDA-approved Wegovy at a subscription price starting around $149/month. In short, it's pivoting from the compounded model toward the branded product.
For a major telehealth platform, that's a notable shift. It signals confidence that branded subscriptions can be priced competitively enough to win over customers who came for the lower cost of compounded medication.
Why It Matters
This move reflects a broader trend: as branded GLP-1 subscriptions get cheaper, the pressure on compounded products is rising. For you, the change is essentially a trade — you give up the rock-bottom price of compounded semaglutide in exchange for the certainty and steady supply of an FDA-approved drug.
Whether that trade is good news depends on your priorities. If you valued the lowest possible price above all, it's a tougher pill; if you'd been a little uneasy about compounded oversight or supply, moving to FDA-approved Wegovy at $149 might actually feel like an upgrade.
What Current Compounded Customers Should Do
If you've been on compounded semaglutide through a platform that's transitioning, don't assume your current product just continues indefinitely. The single best step is to confirm directly what your provider now offers and to plan a smooth switch so you avoid a coverage gap.
Specifically: check whether you're being moved to branded Wegovy and at what price, confirm any dose-conversion details with the prescribing clinician, and time the transition so your new supply arrives before your current one runs out. Treat it like the Ozempic-to-compounded switch in reverse — manageable with a little timing.
Your Options If the New Pricing Doesn't Fit
If $149/month for branded Wegovy doesn't work for your budget, you still have choices. Other licensed, compounding-friendly providers continue to offer compounded semaglutide, so you can move your prescription elsewhere if that's what suits you. Just hold to the usual standards: US-licensed pharmacy, real consultation, transparent pricing.
Alternatively, this could be a moment to reassess the whole menu — savings cards, self-pay vials, the new oral pills — to see if a different route fits you better now. Platform changes are annoying, but they're also a natural prompt to make sure you're on the best option for your current situation.